With 483s from a key set of human clinical study inspections, we used the Redica Systems Expert Model for GCP to show how many inspector observations involving “Responsibilities of the Investigator” fit into several useful subcategories that provide actionable insight for your operations.

“Responsibilities of the investigator” was the largest major category of observations in 483s issued to clinical investigators (CIs) of human clinical studies over the past 20 years.

The second most common type of observation in this key dataset involved “data integrity,” a subject covered in the previous article in this series, “Data Integrity and Your Clinical Investigator: What the Data Shows.”

Redica Systems Senior GMP Quality Expert Jerry Chapman presented our breakdown of “Responsibilities of the Investigator” observations in his April 6 presentation, “Evaluating Clinical Study Deficiencies Found During Inspection Using AI,” at the 2022 Society of Quality Assurance Annual Meeting. The third article in this series will address the results of applying our GCP Expert Model to Warning Letters, and how that result differed from our findings in 483s.

[Related: For more on identifying trends in FDA GCP inspections, download a recording of a webinar featuring Redica Systems Senior GMP Quality Expert Jerry Chapman.]

June webinar - ondemand

Why Did We Choose this Dataset?

We gave this dataset priority because it is fairly representative. According to FDA deficiency statistics, inspections of CIs from 2016-2021 account for about 75% of BIMO inspections. Including inspections of institutional review boards (IRBs) in that total accounts for about 87%. This is why we focused our first GCP expert models on these two areas. The remainder of BIMO inspections were concentrated on sponsors/contract research organizations (CROs)/sponsor investigators. (Note: Our analysis omits GLP, BA/BE, PADE, and REMS inspections.)

GCP Inspection Landscape

Focusing on inspections of CIs, far more of these BIMO inspections (in data covering 2017-2021) resulted in 483s than in Warning Letters; about one-third resulted in 483s, with Warning Letters at fewer than one in 100. And it should also come as no surprise that the No. 1 observation in 483s overall— beyond just CI inspections—is always 21 CFR 312.60, “protocol compliance.”

Our GCP Expert Model supplies the detail behind that broad “protocol compliance” category, showing which aspects of protocol compliance deserve your focused attention because they are often found deficient.

What is truly important is the content of the observations, not the number of observations—though industry lore often gets it backward

How Redica Systems Extracts Crucial Detail

With more than 50,000 unique 483s, 483 Responses, and Establishment Inspection Reports (EIRs), and more, Redica Systems has more publicly available enforcement documents than any other non-governmental entity. Our GXP subject-matter experts, such as Jerry Chapman, build proprietary expert models for each GXP area with the help of dozens of data scientists and engineers. With these GXP Expert Models, a computer algorithm analyzes documents as a human expert would.

To do this, we use optical character recognition to make every document—PDFs included—text-searchable, and we carefully proofread them all. Finally, we parse the text based on logical document sections—each section serves specific functions and features specific language and other properties. Along with properly directing the algorithm’s search, this careful parsing is crucial for avoiding misleading results. Only then are the documents available for analysis.

“Responsibilities of the Investigator” in Our 483 Dataset

Our dataset includes more than 1,200 483s issued to CIs over the past 20 years, which amounts to about 6,700 pages and 2.7 million words.

As we turn our model to this dataset, what do we see?

Our Expert Model for GCP found that nearly 1,000 of these 483s had issues that could be broadly categorized as “responsibilities of the investigator.” It is the largest category by far.

FDA 483 analysis
“Responsibilities of the Investigator” was the largest major category of observation, followed by “Data Integrity” and “Informed Consent.”

Breaking Down “Responsibilities of the Investigator”

We classified observations involving “responsibilities of the investigator” into several major subcategories, then used our GCP Expert Model to see how many of each—and what share of each—existed in a 20-year set of CI 483s. As shown in the figure below, our model categorized 483s into six neat categories of observations, with the three largest categories accounting for nearly 90% of the total:

Responsibilities of the Clinical Investigator
  • General Responsibilities Under §312.60 — Conducted according to investigational plan, otherwise known as protocol compliance
  • General Responsibilities Under §312.60— Three small subcategories not overlapping with protocol compliance
  • Assurance of IRB Review
  • Investigator Record-keeping and Record Retention — Case histories
  • Investigator Record-keeping and Record Retention — Disposition of drug during study
  • Investigator Record-keeping and Record Retention — Miscellaneous
  • Investigator Reports — Financial Disclosure Reports

A Further Breakdown of Protocol Compliance Observations

It is probably no surprise that protocol compliance, otherwise known as “conducted according to investigational plan,” is at the top—it is nearly always the number one observation in 483s.

Would it not be helpful to know the specific protocol violations noted under §312.60?

But what is behind those protocol compliance observations? The Redica Systems Expert Model for GCP breaks it down into six valuable subcategories of §312.60 citations based on our model:

  • Dosing Issue — Incorrect dose or administration
  • Inclusion/exclusion Criteria — Not including or excluding subjects according to pre-determined criteria
  • PI Personal Attention — Problems related to oversight of the principal investigator
  • Lab Issue — Failure to conduct labs on time or to read labs at the right time
  • Assessment Issue — Inappropriately conducted assessments of different types
  • Adverse Event Reporting
FDA 483 Analysis Not According to Plan
Actual, useful subcategories of §312.60 observations showing where you can focus your attention at your own site.

The largest subcategory within protocol compliance observations concerns subject inclusion/exclusion criteria, followed by four other categories in roughly equivalent shares: aspects of dosing, adverse event reporting, lab issues, and assessment issues.

However, these are the general areas where we recommend focussing your attention in operations. These are the areas where the FDA is finding the most issues on inspection—they are the best places to make sure that your site does not have gaps.

But this is not the only way that Redica Systems can help.

How Redica Systems Can Help You

Our models show what the FDA is looking for, and the deficiencies it finds — not just at a high level of detail, but at an actionable level of detail.

And our clients can go beyond seeing observations at a macro level. They can trace them back to specific Warning Letters and specific 483s, giving them a great deal of utility when it comes to due diligence. For example, this utility includes gaining insight into their own operational deficiencies and those of company partners and contract organizations.

Here is how Redica Systems Expert Models for GXP can help you:

  • Vendor Quality — Intelligence to identify and control risk with your critical GLP, GCP, GDP, and GMP vendors

Study startup and ongoing vendor monitoring that draws from full regulatory histories on GLP and GCP vendors.

Strategic inspection preparation based on current inspection findings at your sites and others. Find trends in the data to identify where to focus your attention.

Tactical inspection preparation using complete FDA investigator profiles. What do they tend to look for? What do they tend to find?

Did you miss Part I? Read it here. Part III of this article series provides further insights and conclusions from Jerry Chapman’s SQA presentation.

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Systems

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.